HLA-C and neoplasm: In the monotherapy phase Ia, principally in patients with low/moderate tumour mutational burden, neoantigen-specific T-cell responses were detected via ex vivo ELISPOT assays or MHC multimer analyses in 14/16 patients, and T cells against multiple tumour antigens were also detected in post-treatment biopsies [10].